MCID: BLD051
MIFTS: 47

Blood Coagulation Disease

Categories: Blood diseases, Genetic diseases

Aliases & Classifications for Blood Coagulation Disease

MalaCards integrated aliases for Blood Coagulation Disease:

Name: Blood Coagulation Disease 12 15 17
Blood Coagulation Disorders 74 43 71
Postpartum Coagulation Defect with Delivery 12
Postpartum Coagulation Defect 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1247
ICD9CM 34 286
MeSH 43 D001778
NCIt 49 C2902
SNOMED-CT 67 64779008
ICD10 32 D68.9 O72.3
UMLS 71 C0005779

Summaries for Blood Coagulation Disease

MalaCards based summary : Blood Coagulation Disease, also known as blood coagulation disorders, is related to inherited blood coagulation disease and antithrombin iii deficiency. An important gene associated with Blood Coagulation Disease is U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Anti-inhibitor coagulant complex and Acenocoumarol have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and brain, and related phenotypes are hematopoietic system and cardiovascular system

Wikipedia : 74 Coagulopathy (also called a bleeding disorder) is a condition in which the blood's ability to coagulate... more...

Related Diseases for Blood Coagulation Disease

Diseases in the Blood Coagulation Disease family:

Inherited Blood Coagulation Disease

Diseases related to Blood Coagulation Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 435)
# Related Disease Score Top Affiliating Genes
1 inherited blood coagulation disease 34.5 VWF THBD SERPINC1 PF4 ITGA2B F9
2 antithrombin iii deficiency 32.8 SERPINC1 PF4 F2
3 gray platelet syndrome 32.7 VWF PF4 ITGA2B CD40LG
4 factor vii deficiency 32.7 SERPINC1 F9 F8 F7 F3 F2
5 factor v deficiency 32.7 VWF F9 F8 F7 F3 F2
6 acquired von willebrand syndrome 32.6 VWF U2AF1 F9 F8 F7 F3
7 factor xiii deficiency 32.6 VWF SERPINC1 F9 F8 F7 F3
8 glanzmann thrombasthenia 32.6 VWF PF4 ITGA2B F9 F8 F3
9 bernard-soulier syndrome 32.6 VWF THPO ITGA2B F9 F8 F7
10 prothrombin deficiency, congenital 32.5 SERPINC1 F2
11 hemophilia b 32.5 VWF SERPINC1 PF4 ICOSLG F9 F8
12 hemophilia 31.5 F9 F8 F7
13 hemophilia a 31.2 VWF F9 F8 F7 F3
14 von willebrand's disease 31.2 VWF PF4 F9 F8 F3 F2
15 disseminated intravascular coagulation 31.2 VWF THBD SERPINC1 F9 F7 F3
16 liver cirrhosis 31.1 THPO SERPINC1 F3 F2 ADAMTS13
17 arteriosclerosis 31.1 THBD SERPINC1 ITGA2B F3
18 factor viii deficiency 31.1 VWF ICOSLG F9 F8 F7 F3
19 heparin-induced thrombocytopenia 31.0 SERPINC1 PF4 F3 CD40LG
20 placental abruption 31.0 THBD SERPINC1 F2
21 collagen disease 30.8 VWF ICOSLG H2AC18 CFHR2 CD40LG CCR6
22 factor x deficiency 30.8 VWF F9 F7 F3 F2
23 varicose veins 30.8 VWF THBD SERPINC1 F2
24 portal hypertension 30.7 VWF THPO F3 F2 CD40LG ADAMTS13
25 thrombotic thrombocytopenic purpura 30.7 VWF THBD SERPINC1 F3 CD40LG ADAMTS13
26 thrombophilia due to thrombin defect 30.7 THBD SERPINC1 PF4 F8 F3 F2
27 respiratory failure 30.7 THBD PF4 H2AC18 F3 F2
28 thrombocytopenia 30.7 VWF U2AF1 THPO THBD SERPINC1 PF4
29 thrombosis 30.6 VWF THBD SERPINC1 PF4 MPL ITGA2B
30 thrombophilia 30.6 VWF THBD SERPINC1 PF4 F9 F8
31 thrombophlebitis 30.6 VWF SERPINC1 F8 F7 F3 F2
32 hellp syndrome 30.6 VWF THBD SERPINC1 F3 F2 CD40LG
33 deficiency anemia 30.6 U2AF1 THPO MPL H2AC18 CSF3 ADAMTS13
34 thrombophilia due to activated protein c resistance 30.6 VWF THBD SERPINC1 PF4 F9 F8
35 polycythemia vera 30.6 VWF THPO THBD PF4 MPL F2
36 myeloma, multiple 30.5 U2AF1 ICOSLG H2AC18 F9 CSF3 CD40LG
37 diabetes mellitus 30.5 VWF THBD SERPINC1 PF4 F8 F3
38 leukemia, acute myeloid 30.4 U2AF1 THPO MPL ITGA2B ICOSLG H2AC18
39 purpura 30.4 VWF THPO THBD SERPINC1 MPL ITGA2B
40 vascular disease 30.4 VWF THBD SERPINC1 PF4 ITGA2B F8
41 meningococcemia 29.9 THBD SERPINC1
42 pseudo-von willebrand disease 11.1
43 bleeding disorder, platelet-type, 16 11.1
44 bleeding disorder, platelet-type, 17 11.1
45 scott syndrome 11.1
46 quebec platelet disorder 11.1
47 bleeding disorder, platelet-type, 12 11.1
48 platelet glycoprotein iv deficiency 11.1
49 bleeding disorder, platelet-type, 8 11.1
50 bleeding disorder, platelet-type, 14 11.1

Graphical network of the top 20 diseases related to Blood Coagulation Disease:



Diseases related to Blood Coagulation Disease

Symptoms & Phenotypes for Blood Coagulation Disease

MGI Mouse Phenotypes related to Blood Coagulation Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 ADAMTS13 CCR6 CD40LG CSF3 F2 F3
2 cardiovascular system MP:0005385 9.96 CCR6 CD40LG F2 F3 F7 F9
3 homeostasis/metabolism MP:0005376 9.83 ADAMTS13 CCR6 CD40LG F2 F3 F7
4 immune system MP:0005387 9.47 ADAMTS13 CCR6 CD40LG CSF3 F2 F3

Drugs & Therapeutics for Blood Coagulation Disease

Drugs for Blood Coagulation Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 208)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anti-inhibitor coagulant complex Approved, Investigational Phase 4
2
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
3
Tranexamic Acid Approved Phase 4 1197-18-8 5526
4 fluindione Approved, Investigational Phase 4 957-56-2
5
Phenindione Approved, Investigational Phase 4 83-12-5 4760
6
Protein C Approved Phase 4
7
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
8
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
9
Enoxaparin Approved Phase 4 9005-49-6 772
10
Dalteparin Approved Phase 4 9005-49-6
11
Apixaban Approved Phase 4 503612-47-3 10182969
12
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
13
Thrombin Approved, Investigational Phase 4
14
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
15 Natriuretic Agents Phase 4
16 Hydroxyethyl Starch Derivatives Phase 4
17 Vasopressins Phase 4
18 Deamino Arginine Vasopressin Phase 4
19 Arginine Vasopressin Phase 4
20 Trace Elements Phase 4
21 Micronutrients Phase 4
22 Coagulants Phase 4
23 Nutrients Phase 4
24 Antifibrinolytic Agents Phase 4
25 Hemostatics Phase 4
26 Fibrinolytic Agents Phase 4
27 calcium heparin Phase 4
28 polysaccharide-K Phase 4
29 Hirudins Phase 4
30 Calcium, Dietary Phase 4
31 Heparin, Low-Molecular-Weight Phase 4
32
protease inhibitors Phase 4
33 HIV Protease Inhibitors Phase 4
34 Serine Proteinase Inhibitors Phase 4
35 Antithrombin III Phase 4
36 Factor Xa Inhibitors Phase 4
37 Antithrombins Phase 4
38 Pharmaceutical Solutions Phase 4
39 Analgesics, Non-Narcotic Phase 4
40 Anti-Inflammatory Agents, Non-Steroidal Phase 4
41 Analgesics Phase 4
42 Cyclooxygenase Inhibitors Phase 4
43 Antirheumatic Agents Phase 4
44 Anti-Inflammatory Agents Phase 4
45 Ketorolac Tromethamine Phase 4
46 Thromboplastin Phase 4
47 Protamines Phase 4
48
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
49
Phylloquinone Approved, Investigational Phase 2, Phase 3 84-80-0
50
Edoxaban Approved Phase 2, Phase 3 480449-70-5

Interventional clinical trials:

(show top 50) (show all 357)
# Name Status NCT ID Phase Drugs
1 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
2 Placebo-Controlled, Randomized, Double-Blind Trial of Prophylactic Desmopressin in Heart Valve Surgery Unknown status NCT03343418 Phase 4 Desmopressin;Placebo
3 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Unknown status NCT02270723 Phase 4 5% Human Albumin " Behring";Lactated Ringer
4 Study Using Plasma for Patients Requiring Emergency Surgery: A Randomized Pilot Trial of Early Plasma for Patients Undergoing Emergency Surgery for Hemorrhagic Shock Unknown status NCT01221389 Phase 4 Human Plasma
5 A Phase IV, Randomized, Single Center, Parallel Group Trial of Human Fibrinogen Concentrate (Haemocomplettan) in the Treatment of Dilutional Coagulopathy During Major Pediatric Surgery Completed NCT01487837 Phase 4 Human fibrinogen concentrate
6 Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects With Von Willebrand's Disease. Completed NCT00168090 Phase 4 Blood coagulation Factor VIII and vWF, human
7 Relationship of Edoxaban Plamsa Concentration and Blood Coagulation in Healthy Volunteers Using Standard Laboratory Tests and Viscoelastic Analysis Completed NCT03666650 Phase 4 Edoxaban 60 MG
8 NovoSeven® (rFVIIa) by Single Dose for Home Treatment of Joint Bleeds in Haemophilia Patients With Inhibitors: A Pilot, Double-Blind Study Versus Standard Multiple Doses of NovoSeven® and Open-Label FEIBA® Completed NCT00108797 Phase 4 eptacog alfa (activated);Feiba VH
9 rFVIIa (NovoSeven®) for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors: A Double-blind Study of a Single High Dose Versus Standard Multiple Doses of rFVIIa Completed NCT00571584 Phase 4 activated recombinant human factor VII
10 A UK Open-label, Multicentre, Exploratory Phase II Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
11 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery. A Randomised Clinical Study Completed NCT02009033 Phase 4 Lactated Ringer;Hydroxyethylstarch
12 The Hospital and Economics CERT: Project 1: The Clinical and Economic Implications of Genetic Testing for Warfarin Management Completed NCT00964353 Phase 4 Warfarin
13 Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients With Moderate or Severe Haemophilia A in India Completed NCT03449342 Phase 4 turoctocog alfa
14 An Open-Label, Randomized, Parallel, Multicenter Trial Comparing the Safety and Efficacy of rFVIIa When Administered as i.v. Bolus or i.v. Continuous Infusion to Hemophiliacs With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
15 The Role of Human Fibrinogen Concentrate (RiaSTAP) in Decreasing Blood Loss and the Need for Component Blood Therapy in Infants Undergoing Cardiopulmonary Bypass. Completed NCT02822599 Phase 4 RiaStAP;Saline
16 Early Administration of Fibrinogen Concentrate in Polytraumatized Patients With Thromboelastometry Suggestive of Hypofibrinogenemia: a Randomized Feasibility Trial Completed NCT02864875 Phase 4 Fibrinogen concentrate
17 Comparison of Three Management Strategies for Post Cardiac Surgery Coagulopathy. Completed NCT00188747 Phase 4
18 Coagulopathy During Surgery for the Repair of Extent 4 Thoraco-Abdominal Aortic Aneurysms - Feasibility Study of the Use of Fibrinogen Concentrate by Infusion in Place of Fresh Frozen Plasma. Completed NCT00994045 Phase 4
19 Anticoagulant Clinic-based Shared-care Versus Usual Cate Management of Vitamin K Antagonist Therapy : the Open, Randomized Multicenter Study Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
20 The Assessment of the Minimal Effective and Tolerated Dose of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Completed NCT00904709 Phase 4 tranexamic acid
21 Bivalirudin vs Heparin in Elderly Patients With Acute Coronary Syndrome Undergoing Elective Percutaneous Coronary Intervention Recruiting NCT04046029 Phase 4 Bivalirudin;Heparin
22 Prothrombin Complex Concentrate Versus Fresh Frozen Plasma to Correct Coagulation Disorders in Adult Neurosurgical Patients Recruiting NCT02777424 Phase 4 Prothrombin Complex Concentrate
23 Profilatic Fibrinogen Concentrate Reduces Postoperative Bleeding in Pediatric Cardiac Surgery With Cardiopulmonary Bypass: Randomized Study Recruiting NCT03884725 Phase 4 Fibrinogen Concentrate
24 Evaluation of Residual Anti-Xa Activity As A Function Of Time Following The Last Treatment Dose of Enoxaparin In Patients Presenting For Elective Surgery Recruiting NCT03296033 Phase 4 Enoxaparin;Enoxaparin
25 A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE) Not yet recruiting NCT04128254 Phase 4 Apixaban Oral Tablet
26 Randomized Trial of Reinforcement Learning for the Dosing of Warfarin Not yet recruiting NCT03962400 Phase 4
27 Prospective Evaluation of the Effects of IV Ketorolac on Platelet Function Post-Cesarean Delivery Not yet recruiting NCT03805607 Phase 4 Ketorolac Tromethamine 30 MG/ML;Placebos
28 Indicación de transfusión de Hemoderivados en el Postoperatorio de cirugía Cardiaca Tras la implantación de un Sistema de monitorización de la coagulación a la Cabecera Del Paciente: Tromboelastometría Versus Protocolo Habitual de transfusión Terminated NCT01919840 Phase 4
29 A Pilot Study to Compare the Use of Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months Withdrawn NCT02774317 Phase 4
30 PRospective Evaluation Comparing Initiation of Warfarin StrategiEs (PRECISE): Pharmacogenetic-guided Versus Usual Care Withdrawn NCT00377143 Phase 4 Warfarin Dosing
31 "Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial Unknown status NCT00214656 Phase 3 Recombinant Activated Factor VII
32 An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Coumarin Derivatives in Subjects With Acute Major Bleeding Completed NCT00708435 Phase 3
33 Efficacy and Safety of NNC 0129-0000-1003 During Surgical Procedures in Patients With Haemophilia A Completed NCT01489111 Phase 3 turoctocog alfa pegol
34 A Multi-Centre, Open-Label, Single-Arm and Multiple Dosing Trial on Efficacy and Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency Completed NCT00713648 Phase 3 catridecacog
35 Randomised, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase®) in Acute Intracerebral Haemorrhage Completed NCT00127283 Phase 3 eptacog alfa (activated)
36 A Multi-national Trial Evaluating Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Patients With Haemophilia A Completed NCT01480180 Phase 3 turoctocog alfa pegol
37 Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients With Congenital Haemophilia and Inhibitors Completed NCT01392547 Phase 3 vatreptacog alfa (activated);eptacog alfa (activated)
38 An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Patients With Haemophilia B Completed NCT01386528 Phase 3 nonacog beta pegol
39 Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies Completed NCT01178294 Phase 2, Phase 3
40 An Open-label, Uncontrolled, Single-arm, Multicenter Phase IIIb Study to Assess the Efficacy and Safety of BE1116 in Japanese Subjects Receiving Vitamin K Antagonist Therapy With an Elevated INR and Either Acute Major Bleeding or a Requirement for Urgent Reversal of Vitamin K Antagonist Therapy for a Surgical or Invasive Medical Procedure Completed NCT02281201 Phase 3
41 An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P/N Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure Completed NCT00803101 Phase 3
42 A Randomised, Double-blind, Parallel Group, Placebo-controlled Comparison of Recombi-nant Factor VIIa (rFVIIa/ NovoSeven®) With Standard Haemostatic Replacement Therapy, and Standard Haemostatic Replacement Ther-apy Following Cardiac Bypass Surgery for Paediatric Congenital Heart Disease Completed NCT01562574 Phase 3 activated recombinant human factor VII;placebo
43 A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A Completed NCT01731600 Phase 3 turoctocog alfa pegol
44 Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Paediatric Previously Untreated Patients With Haemophilia A Completed NCT01493778 Phase 3 turoctocog alfa
45 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects With Severe Sepsis and Coagulopathy. Completed NCT01598831 Phase 3 ART-123;Placebo
46 A Multi-Centre, Open-Label, Single-Arm, and Multiple Dosing Trial on Safety of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Subjects With Congenital Factor XIII Deficiency Completed NCT00978380 Phase 3 catridecacog
47 Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A Completed NCT02938585 Phase 3 turoctocog alfa;turoctocog alfa
48 A Phase 3b Trial Investigating the Pharmacokinetics and Safety Profile of a Single Intravenous Dose of rFXIII in Paediatric (1 to Less Than 6 Years Old) Subjects With Congenital FXIII A-subunit Deficiency Completed NCT01230021 Phase 3 catridecacog
49 A Two Part Randomized Cross-Over Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety Profile of Plasma Protein-Free Recombinant FVIII Formulated With Sucrose (BAY81-8973) in Previously Treated Subjects With Severe Hemophilia A Under Prophylaxis Therapy Completed NCT01029340 Phase 3
50 Cooperative Study of Factor VIII Inhibitors Completed NCT00000582 Phase 3 factor ix

Search NIH Clinical Center for Blood Coagulation Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Tranexamic Acid
TRANEXAMIC ACID PWDR

Cochrane evidence based reviews: blood coagulation disorders

Genetic Tests for Blood Coagulation Disease

Anatomical Context for Blood Coagulation Disease

MalaCards organs/tissues related to Blood Coagulation Disease:

40
Testes, Liver, Brain, Heart, Whole Blood, Prostate, Kidney

Publications for Blood Coagulation Disease

Articles related to Blood Coagulation Disease:

(show top 50) (show all 444)
# Title Authors PMID Year
1
Coagulation System Disorders and Thrombosis Prophylaxis During Laparoscopic Fundoplications. 61
31517745 2019
2
Contribution of nascent cohesive fiber-fiber interactions to the non-linear elasticity of fibrin networks under tensile load. 61
31152942 2019
3
[Blood Coagulation Disorders During ECMO and LVAD Therapy]. 61
31212331 2019
4
Hepatectomy in patients with inherited blood coagulation disorders can be safely performed with adequate coagulation factor replacement. 61
31144420 2019
5
[The condition of the hemostatic system in acute severe peritonitis during remaxol therapy]. 61
30855593 2019
6
In vitro anticoagulant effect of Crassocephalum crepidioides leaf methanol extract and fractions on human blood. 61
31564995 2019
7
Distinct plasma proteomic changes in male and female African American stroke patients. 61
31149323 2019
8
Suprachoroideal haemorrhage in postoperative period of antiglaucoma surgery, case report. 61
31537078 2019
9
[A case of congenital bile acid synthesis disorder type 2 and literature review]. 61
30298497 2018
10
The characteristics of beta 2-glycoprotein I-dependent anticardiolipin antibody and blood coagulation status in subjects with classical biological false-positive syphilis reactions. 61
30005228 2018
11
Hemorrhagic Events in Adult Celiac Disease Patients. Case Report and Review of the Literature. 61
29557421 2018
12
Microbial serine protease inhibitors and their therapeutic applications. 61
28970170 2018
13
Correlations between lipid metabolism indices in patients with hypertension and hypothyroidism. 61
29729156 2018
14
Thrombosis in Thyroid Cancer. 61
29696039 2018
15
A User-Friendly App for Blood Coagulation Disorders. 61
29380340 2018
16
Hemostasis in Overt and Subclinical Hyperthyroidism. 61
29201071 2017
17
Hemostasis in Hypothyroidism and Autoimmune Thyroid Disorders. 61
29026409 2017
18
Thromboelastographic profile of goat blood after the experimental injury of the femoral artery and use of QuikClot gauze and Celox gauze dressings. 61
28525329 2017
19
Measuring coagulation in burns: an evidence-based systematic review. 61
29799542 2017
20
Novel combined strategy of obstetric haemorrhage management during caesarean section using intrauterine balloon tamponade. 61
26625194 2017
21
Treatment of Coagulopathy Related to Hepatic Insufficiency. 61
27635482 2016
22
Possibly propylthiouracil-induced antineutrophilic cytoplasmic antibody-associated vasculitis manifested as blood coagulation disorders: A case report. 61
27741122 2016
23
Protease-activated receptors - biology and role in cancer. 61
27383574 2016
24
Biomedical and Catalytic Applications of Gold and Silver-Gold Alloy Nanoparticles Biosynthesized Using Cell-Free Extract of Bacillus Safensis LAU 13: Antifungal, Dye Degradation, Anti-Coagulant and Thrombolytic Activities. 61
27164598 2016
25
Untangling the complexity of blood coagulation network: use of computational modelling in pharmacology and diagnostics. 61
26116831 2016
26
A portable blood plasma clot micro-elastometry device based on resonant acoustic spectroscopy. 61
26233406 2015
27
The influence of joint application of arsenic trioxide and daunorubicin on primary acute promyelocytic leukaemia cells and apoptosis and blood coagulation of cell strain. 61
26051726 2015
28
[Anesthesia and perioperative management for cesarean section in patient with factor XI deficiency: a case report]. 61
24743832 2014
29
A conformational investigation of propeptide binding to the integral membrane protein γ-glutamyl carboxylase using nanodisc hydrogen exchange mass spectrometry. 61
24512177 2014
30
Discovery of glycyrrhetinic acid as an orally active, direct inhibitor of blood coagulation factor xa. 61
24412029 2014
31
[Features of coagulative blood potential disorder in acute constitutional inflammatory response of septic tubo-ovarian formations]. 61
25971120 2014
32
[Overview--Recent therapeutic strategy for blood coagulation disorders]. 61
24492038 2014
33
TURP and PVP treatments are really similar? From subjective feeling to objective data. Pilot study (proof of concept) prospective randomized trial. 61
23427748 2012
34
Quantification of circulating D-dimer by peptide immunoaffinity enrichment and tandem mass spectrometry. 61
22788854 2012
35
[Bundle program of treatment for acute severe type high altitude disease]. 61
22748458 2012
36
[Neonatal renal vein thrombosis in a heterozygous carrier of both factor V Leiden and the MTHFR gene mutation]. 61
22361411 2012
37
[Epidural analgesia for surgical treatment of peritoneal carcinomatosis: a risky technique?]. 61
22154448 2012
38
Chapter 9: Analyses using disease ontologies. 61
23300417 2012
39
Non-cirrhotic portal hypertension with large regenerative nodules: a diagnostic challenge. 61
21633664 2011
40
Malignant tumours of colon and rectum from the blood clotting view. 61
22180990 2011
41
D-dimer, plasminogen activator inhibitor-1, prothrombin fragments and protein C - role in prothrombotic state of colorectal cancer. 61
21391740 2011
42
Spontaneous intramural duodenal haematoma with transient biliary obstruction and acute cholecystitis. 61
21221492 2010
43
Comparison of the fibrinogen Clauss assay and the fibrinogen PT derived method in patients with dysfibrinogenemia. 61
20947138 2010
44
Ophidian accident-related multi-organ failure: a case report. 61
25302518 2010
45
[Diagnosis and correction of thrombohemorrhagic complications in cardiosurgical patients in the early postoperative period]. 61
21400731 2010
46
In silico studies of blood coagulation proteins: from mosaic proteases to nonenzymatic cofactor inhibitors. 61
20083402 2010
47
Purification and functional characterisation of rhinocerase, a novel serine protease from the venom of Bitis gabonica rhinoceros. 61
20300193 2010
48
Blood coagulation disorders in septic patients. 61
20364416 2010
49
Role of fibrinogen-, factor VIII- and XIII-mediated clot propagation in gelatin haemodilution. 61
19239406 2009
50
Atypical causes of nontraumatic intracranial subarachnoid hemorrhage. 61
19117667 2009

Variations for Blood Coagulation Disease

Expression for Blood Coagulation Disease

Search GEO for disease gene expression data for Blood Coagulation Disease.

Pathways for Blood Coagulation Disease

Pathways related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 VWF THPO THBD SERPINC1 PF4 MPL
2
Show member pathways
12.59 THBD SERPINC1 F9 F8 F7 F3
3
Show member pathways
11.81 VWF THBD SERPINC1 PF4 F9 F8
4 11.77 THPO MPL ITGA2B CSF3
5
Show member pathways
11.65 VWF THPO MPL ITGA2B F2
6 11.44 VWF THBD SERPINC1 F9 F8 F7
7 11.32 VWF ITGA2B F2
8 10.76 THPO PF4 ITGA2B CSF3 CD40LG
9 10.72 F9 F7 F2

GO Terms for Blood Coagulation Disease

Cellular components related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.87 THBD MPL ITGA2B F3 CD40LG CCR6
2 external side of plasma membrane GO:0009897 9.8 ITGA2B ICOSLG F2 CD40LG CCR6
3 extracellular region GO:0005576 9.77 VWF THPO SERPINC1 PF4 F9 F8
4 endoplasmic reticulum lumen GO:0005788 9.73 SERPINC1 F9 F8 F7 F2 ADAMTS13
5 collagen-containing extracellular matrix GO:0062023 9.7 VWF SERPINC1 PF4 F9 F7 F3
6 platelet alpha granule lumen GO:0031093 9.61 VWF PF4 F8
7 extracellular space GO:0005615 9.4 THPO THBD SERPINC1 PF4 F9 F8
8 serine-type peptidase complex GO:1905286 9.37 F7 F3

Biological processes related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 ER to Golgi vesicle-mediated transport GO:0006888 9.8 F9 F8 F7 F2
2 positive regulation of protein kinase B signaling GO:0051897 9.76 THPO F7 F3 CSF3
3 protein processing GO:0016485 9.65 F7 F3 ADAMTS13
4 platelet activation GO:0030168 9.63 VWF PF4 F8 F2 CD40LG ADAMTS13
5 platelet degranulation GO:0002576 9.62 VWF PF4 ITGA2B F8
6 blood coagulation GO:0007596 9.61 VWF THBD SERPINC1 F9 F8 F7
7 positive regulation of blood coagulation GO:0030194 9.56 F7 F2
8 blood coagulation, intrinsic pathway GO:0007597 9.56 VWF F9 F8 F2
9 positive regulation of positive chemotaxis GO:0050927 9.55 F7 F3
10 regulation of blood coagulation GO:0030193 9.54 SERPINC1 F2
11 negative regulation of fibrinolysis GO:0051918 9.52 THBD F2
12 negative regulation of platelet activation GO:0010544 9.51 THBD F2
13 thrombopoietin-mediated signaling pathway GO:0038163 9.43 THPO MPL
14 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.4 F7 F3
15 blood coagulation, extrinsic pathway GO:0007598 9.37 F7 F3
16 hemostasis GO:0007599 9.28 VWF THBD SERPINC1 F9 F8 F7

Molecular functions related to Blood Coagulation Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 THPO PF4 CSF3 CD40LG
2 serine-type endopeptidase activity GO:0004252 8.92 F9 F7 F3 F2

Sources for Blood Coagulation Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....